ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Letian Zhang
Matched on ORCID iD 0000-0002-3373-5615; OpenAlex author ID A5039034935. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers
Papers 8
- Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer. First author DOI 10.1016/j.radonc.2025.111210↗
- Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1186/s12885-025-13799-5↗
- Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-institution cohort and SEER database analysis. First author DOI 10.3389/fonc.2024.1473251↗
- Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer. Co-author DOI 10.3748/wjg.v30.i12.1739↗
- Survival Outcomes and Failure Patterns in Patients with Inoperable Non-Metastatic Pancreatic Cancer Treated with Definitive Radiotherapy. First author DOI 10.3390/cancers15082213↗
- Survival benefits and disparities in radiation therapy for elderly patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.4251/wjgo.v15.i1.155↗
- Risk factors, prognostic predictors, and nomograms for liver metastasis in patients with pancreatic cancer: a population-based study. Co-author DOI 10.21203/rs.3.rs-1550766/v1↗
- Identify Prognostic Factors and Establish a Risk Stratification Model to Predict Cancer-Specific Survival for Patients with Pancreatic Cancer Liver Metastasis:… Co-author DOI 10.21203/rs.3.rs-855925/v1↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Biyang Cao · 8 shared papers, 2021–2025 · strength 1.94
- Paper Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer. DOI 10.1016/j.radonc.2025.111210↗
- Paper Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-instituti… DOI 10.3389/fonc.2024.1473251↗
- Paper Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer. DOI 10.3748/wjg.v30.i12.1739↗
- Jing Wang · 6 shared papers, 2021–2025 · strength 1.51
- Paper Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer. DOI 10.1016/j.radonc.2025.111210↗
- Paper Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-instituti… DOI 10.3389/fonc.2024.1473251↗
- Paper Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer. DOI 10.3748/wjg.v30.i12.1739↗
- Lin Yang · 2 shared papers, 2024–2025 · strength 0.50
- Paper Survival benefits of radiotherapy in locally advanced unresectable and metastatic pancreatic cancer: a single-instituti… DOI 10.3389/fonc.2024.1473251↗
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5↗
- Wen Zhang · 1 shared paper, 2025 · strength 0.22
- Wenwei Yang · 1 shared paper, 2025 · strength 0.22
- Xiaoting Ma · 1 shared paper, 2025 · strength 0.22
- Kai Ou · 1 shared paper, 2025 · strength 0.22
- Jing Wang · 1 shared paper, 2022 · strength 0.20
- Qianqian Wang · 1 shared paper, 2023 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.